{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:53:17Z","timestamp":1782906797866,"version":"3.54.5"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.canrad.2026.104810","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:00:16Z","timestamp":1780423216000},"page":"104810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Magnetic resonance imaging-guided radiotherapy for prostate cancer: A systematic review of the literature"],"prefix":"10.1016","volume":"30","author":[{"given":"Sara-Lydia","family":"Adoum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Baty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le Gu\u00e9velou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lafond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chapet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Truc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naji","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"de Crevoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.canrad.2026.104810_bib0520","first-page":"F394","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de canc\u00e9rologie de l\u2019Afu-Actualisation 2024\u20132026\u00a0: cancer de la prostate-diagnostic et prise en charge de la maladie localis\u00e9e","volume":"34","author":"Ploussard","year":"2024","journal-title":"Prog Urol\u00a0\u2013\u00a0FMC"},{"issue":"5","key":"10.1016\/j.canrad.2026.104810_bib0525","doi-asserted-by":"crossref","first-page":"e0154499","DOI":"10.1371\/journal.pone.0154499","article-title":"The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures","volume":"11","author":"Yu","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0530","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0167-8140(99)00100-0","article-title":"Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer","volume":"55","author":"Zelefsky","year":"2000","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0535","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2010.05.008","article-title":"Characterizing Interfraction variations and their dosimetric effects in prostate cancer radiotherapy","volume":"79","author":"Peng","year":"2011","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0540","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.radonc.2016.04.014","article-title":"MRI-guided prostate adaptive radiotherapy\u00a0\u2013\u00a0a systematic review","volume":"119","author":"McPartlin","year":"2016","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0545","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijrobp.2011.11.047","article-title":"Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer","volume":"84","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol"},{"issue":"1\u20132","key":"10.1016\/j.canrad.2026.104810_bib0550","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canrad.2021.08.002","article-title":"Image-guided radiotherapy","volume":"26","author":"de Crevoisier","year":"2022","journal-title":"Cancer Radiother"},{"issue":"1\u20132","key":"10.1016\/j.canrad.2026.104810_bib0555","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.canrad.2021.11.017","article-title":"External radiotherapy for prostatic cancers","volume":"26","author":"de Crevoisier","year":"2022","journal-title":"Cancer Radiother"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0560","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2=1.4 (0.9\u20132.2)\u00a0Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol"},{"issue":"8","key":"10.1016\/j.canrad.2026.104810_bib0565","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0570","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1748-717X-9-22","article-title":"Change in prostate volume during extreme hypofractionation analysed with MRI","volume":"9","author":"Gunnlaugsson","year":"2014","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2026.104810_bib0575","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0580","first-page":"35","article-title":"Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: initial clinical experiences and assessment of delivered doses compared to a C-arm linac","volume":"23","author":"Dunlop","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2026.104810_bib0585","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/mrm.29564","article-title":"A pilot study of MRI radiomics for high-risk prostate cancer stratification in 1.5T MR-guided radiotherapy","volume":"89","author":"Zhou","year":"2023","journal-title":"Magn Reson Med"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0590","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs. computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2026.104810_bib0595","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2024.10.026","article-title":"Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial","volume":"87","author":"Kishan","year":"2025","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.canrad.2026.104810_bib0600","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: early toxicity results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0605","doi-asserted-by":"crossref","first-page":"1151256","DOI":"10.3389\/fonc.2023.1151256","article-title":"Outcome of the first 200 patients with prostate cancer treated with MRI-Linac at Assuta MC","volume":"13","author":"Gelbart Pridan","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2026.104810_bib0610","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.3390\/curroncol31050203","article-title":"Online adaptive MR-guided ultrahypofractionated radiotherapy of prostate cancer on a 1.5T MR-linac: clinical experience and prospective evaluation","volume":"31","author":"Potkrajcic","year":"2024","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0615","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13014-020-01510-w","article-title":"1.5T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment","volume":"15","author":"Alongi","year":"2020","journal-title":"Radiat Oncol"},{"issue":"12","key":"10.1016\/j.canrad.2026.104810_bib0620","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.3390\/jpm12121982","article-title":"1.5T MR-guided daily-adaptive SBRT for prostate cancer: preliminary report of toxicity and quality of life of the first 100 patients","volume":"12","author":"Alongi","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.canrad.2026.104810_bib0625","first-page":"100771","article-title":"Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer-acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial","volume":"46","author":"Fink","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0630","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241270595","article-title":"Clinical outcomes of prostate SBRT using non-adaptive MR-guided radiotherapy","volume":"31","author":"Sandoval","year":"2024","journal-title":"Cancer Control"},{"key":"10.1016\/j.canrad.2026.104810_bib0635","first-page":"100742","article-title":"MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study","volume":"46","author":"Sritharan","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0640","doi-asserted-by":"crossref","first-page":"909402","DOI":"10.3389\/fonc.2022.909402","article-title":"Clinical utility of a 1.5T magnetic resonance imaging-guided linear accelerator during conventionally fractionated and hypofractionated prostate cancer radiotherapy","volume":"12","author":"Turkkan","year":"2022","journal-title":"Front Oncol"},{"issue":"1117","key":"10.1016\/j.canrad.2026.104810_bib0645","doi-asserted-by":"crossref","first-page":"20200696","DOI":"10.1259\/bjr.20200696","article-title":"Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity","volume":"94","author":"Ugurluer","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2026.104810_bib0650","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.phro.2019.02.002","article-title":"Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer","volume":"9","author":"Tetar","year":"2019","journal-title":"Phys Imaging Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0655","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.prro.2022.09.007","article-title":"Magnetic resonance-guided adaptive radiation therapy for prostate cancer: the first results from the MOMENTUM study\u00a0\u2014\u00a0an international registry for the evidence-based introduction of magnetic resonance-guided adaptive radiation therapy","volume":"13","author":"Teunissen","year":"2023","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2026.104810_bib0660","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s11547-023-01624-7","article-title":"Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability","volume":"128","author":"Nicosia","year":"2023","journal-title":"Radiol Med (Torino)"},{"issue":"10","key":"10.1016\/j.canrad.2026.104810_bib0665","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.21037\/tcr-23-611","article-title":"Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer: more than a simple \u201cMIRAGE\u201d?","volume":"12","author":"Bosetti","year":"2023","journal-title":"Transl Cancer Res"},{"issue":"19","key":"10.1016\/j.canrad.2026.104810_bib0670","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/cncr.34836","article-title":"Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: a systematic review and meta-analysis","volume":"129","author":"Leeman","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2026.104810_bib0675","doi-asserted-by":"crossref","first-page":"962897","DOI":"10.3389\/fonc.2022.962897","article-title":"Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology","volume":"12","author":"Hall","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0680","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"issue":"7","key":"10.1016\/j.canrad.2026.104810_bib0685","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0690","doi-asserted-by":"crossref","first-page":"109441","DOI":"10.1016\/j.radonc.2022.109441","article-title":"SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: an analysis of the dosimetric impact of intrafractional organ changes","volume":"179","author":"Brennan","year":"2023","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0695","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2023.09.032","article-title":"Interim toxicity analysis from the randomized HERMES trial of 2- and 5-fraction magnetic resonance imaging-guided adaptive prostate radiation therapy","volume":"118","author":"Westley","year":"2024","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2026.104810_bib0700","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.prro.2024.10.009","article-title":"Simulation of focal boosting in online adaptive MRI-guided SBRT for patients with locally advanced prostate cancer with seminal vesicle involvement","volume":"15","author":"Dassen","year":"2025","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0705","first-page":"10","article-title":"Dosimetric evaluation of ultrafractionated dose escalation with simultaneous integrated boost to intraprostatic lesion using 1.5-Tesla MR-linac in localized prostate cancer","volume":"29","author":"Onal","year":"2024","journal-title":"Rep Pract Oncol Radiother"},{"issue":"2","key":"10.1016\/j.canrad.2026.104810_bib0710","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2020.01.052","article-title":"trial of MRI-guided prostate cancer lattice extreme ablative dose (LEAD) boost radiation therapy","volume":"107","author":"Pollack","year":"2020","journal-title":"Int J Radiat Oncol"},{"issue":"10260","key":"10.1016\/j.canrad.2026.104810_bib0715","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"issue":"10260","key":"10.1016\/j.canrad.2026.104810_bib0720","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0725","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijrobp.2022.08.041","article-title":"Quality-of-life outcomes and toxicity profile among patients with localized prostate cancer after radical prostatectomy treated with stereotactic body radiation: the SCIMITAR multicenter phase 2 trial","volume":"115","author":"Ma","year":"2023","journal-title":"Int J Radiat Oncol"},{"issue":"16","key":"10.1016\/j.canrad.2026.104810_bib0730","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.3390\/jcm11164651","article-title":"First experience and prospective evaluation on feasibility and acute toxicity of online adaptive radiotherapy of the prostate bed as salvage treatment in patients with biochemically recurrent prostate cancer on a 1.5T MR-linac","volume":"11","author":"Wegener","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0735","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1186\/s12885-023-11278-3","article-title":"Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)","volume":"23","author":"Marciscano","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2026.104810_bib0740","doi-asserted-by":"crossref","first-page":"962897","DOI":"10.3389\/fonc.2022.962897","article-title":"Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology","volume":"12","author":"Hall","year":"2022","journal-title":"Front Oncol"},{"issue":"15","key":"10.1016\/j.canrad.2026.104810_bib0745","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.purol.2012.07.005","article-title":"\u00c9tude qualitative de la continence urinaire apr\u00e8s prostatectomie radicale laparoscopique","volume":"22","author":"Erauso","year":"2012","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.canrad.2026.104810_bib0750","doi-asserted-by":"crossref","first-page":"100748","DOI":"10.1016\/j.adro.2021.100748","article-title":"Magnetic resonance-guided reirradiation for local recurrence within the prostate or in the prostate bed: preliminary results of a prospective registry study","volume":"6","author":"Michalet","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0755","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13014-023-02271-y","article-title":"Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis","volume":"18","author":"Boldrini","year":"2023","journal-title":"Radiat Oncol"},{"issue":"8","key":"10.1016\/j.canrad.2026.104810_bib0760","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3390\/cancers14081943","article-title":"Magnetic resonance-guided reirradiation for local recurrence within the prostate or in the prostate bed: one-year clinical results of a prospective registry study","volume":"14","author":"Michalet","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canrad.2026.104810_bib0765","doi-asserted-by":"crossref","first-page":"858740","DOI":"10.3389\/fonc.2022.858740","article-title":"1.5T MR-guided daily adaptive stereotactic body radiotherapy for prostate re-irradiation: a preliminary report of toxicity and clinical outcomes","volume":"12","author":"Cuccia","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0770","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/acm2.12529","article-title":"Improving fiducial and prostate capsule visualization for radiotherapy planning using MRI","volume":"20","author":"Pathmanathan","year":"2019","journal-title":"J Appl Clin Med Phys"},{"issue":"7","key":"10.1016\/j.canrad.2026.104810_bib0775","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3390\/cancers13071533","article-title":"Prospective image quality and lesion assessment in the setting of MR-guided radiation therapy of prostate cancer on an MR-linac at 1.5T: a comparison to a standard 3T MRI","volume":"13","author":"Almansour","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.canrad.2026.104810_bib0780","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2478\/raon-2023-0020","article-title":"Longitudinal monitoring of apparent diffusion coefficient (ADC) in patients with prostate cancer undergoing MR-guided radiotherapy on an MR-linac at 1.5T: a prospective feasibility study","volume":"57","author":"Almansour","year":"2023","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0785","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mri.2024.03.020","article-title":"Prostate diffusion-weighted imaging (DWI) in MR-guided radiotherapy: reproducibility assessment on 1.5T MR-linac and 1.5T MR-simulator","volume":"111","author":"Wong","year":"2024","journal-title":"Magn Reson Imaging"},{"issue":"2","key":"10.1016\/j.canrad.2026.104810_bib0790","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.21037\/qims-21-697","article-title":"A narrative review of MRI acquisition for MR-guided-radiotherapy in prostate cancer","volume":"12","author":"Yuan","year":"2022","journal-title":"Quant Imaging Med Surg"},{"issue":"1073","key":"10.1016\/j.canrad.2026.104810_bib0795","doi-asserted-by":"crossref","first-page":"20160667","DOI":"10.1259\/bjr.20160667","article-title":"The future of image-guided radiotherapy will be MR guided","volume":"90","author":"Pollard","year":"2017","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0800","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"issue":"9","key":"10.1016\/j.canrad.2026.104810_bib0805","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/0284186X.2015.1062541","article-title":"Comparison of onboard low-field magnetic resonance imaging versus onboard computed tomography for anatomy visualization in radiotherapy","volume":"54","author":"Noel","year":"2015","journal-title":"Acta Oncol"},{"issue":"1096","key":"10.1016\/j.canrad.2026.104810_bib0810","doi-asserted-by":"crossref","first-page":"20180948","DOI":"10.1259\/bjr.20180948","article-title":"Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy","volume":"92","author":"Pathmanathan","year":"2019","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0815","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0167-8140(98)00021-8","article-title":"Intra- and interobserver variability in contouring prostate and seminal vesicles: implications for conformal treatment planning","volume":"47","author":"Fiorino","year":"1998","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0820","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2008.11.015","article-title":"Prostate delineation using CT and MRI for radiotherapy patients with bilateral hip prostheses","volume":"90","author":"Rosewall","year":"2009","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2026.104810_bib0825","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.rpor.2020.03.014","article-title":"Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (part III on psychosexual therapy and the masculine self-esteem)","volume":"25","author":"Ramirez-Fort","year":"2020","journal-title":"Rep Pract Oncol Radiother"},{"issue":"4","key":"10.1016\/j.canrad.2026.104810_bib0830","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.eururo.2017.02.007","article-title":"Vessel-sparing radiotherapy for localized prostate cancer to preserve erectile function: a single-arm phase 2 trial","volume":"72","author":"Spratt","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.canrad.2026.104810_bib0835","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0090-4295(01)00940-2","article-title":"Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer","volume":"57","author":"Fisch","year":"2001","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.canrad.2026.104810_bib0840","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2017.10.020","article-title":"Magnetic resonance imaging-guided adaptive radiation therapy: a \u201cgame changer\u201d for prostate treatment?","volume":"100","author":"Pathmanathan","year":"2018","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0845","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol"},{"issue":"14","key":"10.1016\/j.canrad.2026.104810_bib0850","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.3390\/cancers13143564","article-title":"Evaluation of T2-weighted MRI for visualization and sparing of urethra with MR-guided radiation therapy (MRgRT) onboard MRI","volume":"13","author":"Pham","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.canrad.2026.104810_bib0855","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0860","first-page":"100907","article-title":"Urethra-sparing prostate cancer radiotherapy: current practices and future insights from an international survey","volume":"51","author":"Le Gu\u00e9velou","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0865","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijrobp.2022.01.022","article-title":"Intraprostatic urethra: the new kid on the block for prostate cancer radiation therapy?","volume":"113","author":"Zilli","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0870","doi-asserted-by":"crossref","DOI":"10.1177\/15330338241297231","article-title":"MR-guided adaptive radiotherapy in localized prostate cancer","volume":"24","author":"Allegra","year":"2025","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.canrad.2026.104810_bib0875","first-page":"54","article-title":"Adaptive radiotherapy: the Elekta Unity MR-linac concept","volume":"18","author":"Winkel","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0880","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.semradonc.2014.02.008","article-title":"The ViewRay system: magnetic resonance-guided and controlled radiotherapy","volume":"24","author":"Mutic","year":"2014","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2026.104810_bib0885","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1118\/1.1851920","article-title":"Use and uncertainties of mutual information for computed tomography\/magnetic resonance (CT\/MR) registration post-permanent implant of the prostate: mutual information for CT\/MR registration of the prostate","volume":"32","author":"Roberson","year":"2005","journal-title":"Med Phys"},{"issue":"22","key":"10.1016\/j.canrad.2026.104810_bib0890","doi-asserted-by":"crossref","first-page":"R323","DOI":"10.1088\/0031-9155\/60\/22\/R323","article-title":"Radiotherapy planning using MRI","volume":"60","author":"Schmidt","year":"2015","journal-title":"Phys Med Biol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0895","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13014-017-0854-4","article-title":"Clinical workflow for MR-only simulation and planning in prostate","volume":"12","author":"Tyagi","year":"2017","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0900","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.ijrobp.2011.11.056","article-title":"An atlas-based electron density mapping method for magnetic resonance imaging (MRI)-alone treatment planning and adaptive MRI-based prostate radiation therapy","volume":"83","author":"Dowling","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0905","doi-asserted-by":"crossref","first-page":"969463","DOI":"10.3389\/fonc.2022.969463","article-title":"Synthetic CT generation for MRI-guided adaptive radiotherapy in prostate cancer","volume":"12","author":"Hsu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0910","doi-asserted-by":"crossref","first-page":"110043","DOI":"10.1016\/j.radonc.2023.110043","article-title":"Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity","volume":"190","author":"Nicosia","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0915","doi-asserted-by":"crossref","first-page":"1379596","DOI":"10.3389\/fonc.2024.1379596","article-title":"Magnetic resonance image-guided adaptive radiotherapy enables safe CTV-to-PTV margin reduction in prostate cancer: a cine MRI motion study","volume":"14","author":"Westley","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0920","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tipsro.2022.08.005","article-title":"Impact of intrafraction changes in delivered dose of the day for prostate cancer patients treated with stereotactic body radiotherapy via MR-linac","volume":"23","author":"Dang","year":"2022","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"issue":"14","key":"10.1016\/j.canrad.2026.104810_bib0925","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1088\/0031-9155\/58\/14\/4921","article-title":"Reduction of prostate intrafractional motion from shortening the treatment time","volume":"58","author":"Li","year":"2013","journal-title":"Phys Med Biol"},{"issue":"5","key":"10.1016\/j.canrad.2026.104810_bib0930","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.ijrobp.2023.12.035","article-title":"Quantifying intrafraction motion and the impact of gating for magnetic resonance imaging-guided stereotactic radiation therapy for prostate cancer: analysis of the magnetic resonance imaging arm from the MIRAGE phase 3 randomized trial","volume":"118","author":"Neylon","year":"2024","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0935","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.meddos.2005.03.005","article-title":"A review of prostate motion with considerations for the treatment of prostate cancer","volume":"30","author":"Byrne","year":"2005","journal-title":"Med Dosim"},{"issue":"2","key":"10.1016\/j.canrad.2026.104810_bib0940","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/COC.0b013e3181a31c1a","article-title":"A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy","volume":"33","author":"Frank","year":"2010","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0945","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1748-717X-7-139","article-title":"Seminal vesicle interfraction displacement and margins in image guided radiotherapy for prostate cancer","volume":"7","author":"Mak","year":"2012","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104810_bib0950","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0360-3016(02)03011-0","article-title":"Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume?","volume":"54","author":"Kestin","year":"2002","journal-title":"Int J Radiat Oncol"},{"issue":"8","key":"10.1016\/j.canrad.2026.104810_bib0955","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1118\/1.2952443","article-title":"An on-line replanning scheme for interfractional variations: online replanning","volume":"35","author":"Ahunbay","year":"2008","journal-title":"Med Phys"},{"issue":"2","key":"10.1016\/j.canrad.2026.104810_bib0960","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/0284186X.2020.1821090","article-title":"Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy","volume":"60","author":"Nicosia","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0965","doi-asserted-by":"crossref","first-page":"1039901","DOI":"10.3389\/fonc.2023.1039901","article-title":"Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-linac","volume":"13","author":"Gao","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0970","first-page":"51","article-title":"Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-linac: estimated delivered dose and early toxicity results","volume":"10","author":"Gao","year":"2024","journal-title":"Chronic Dis Transl Med"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0975","doi-asserted-by":"crossref","first-page":"e14179","DOI":"10.1002\/acm2.14179","article-title":"The impact of margin reduction on radiation dose distribution of ultra-hypofractionated prostate radiotherapy utilizing a 1.5-T MR-linac","volume":"25","author":"Onal","year":"2024","journal-title":"J Appl Clin Med Phys"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib0980","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13014-020-01604-5","article-title":"Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow","volume":"15","author":"Mannerberg","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib0985","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejmp.2020.09.026","article-title":"Adaptive SBRT by 1.5T MR-linac for prostate cancer: on the accuracy of dose delivery in view of the prolonged session time","volume":"80","author":"Ruggieri","year":"2020","journal-title":"Phys Med"},{"key":"10.1016\/j.canrad.2026.104810_bib0990","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tipsro.2022.02.002","article-title":"Bladder filling in patients undergoing prostate radiotherapy on a MR-linac: the dosimetric impact","volume":"21","author":"Smith","year":"2022","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"issue":"12","key":"10.1016\/j.canrad.2026.104810_bib0995","doi-asserted-by":"crossref","first-page":"e14122","DOI":"10.1002\/acm2.14122","article-title":"Evaluation of Unity 1.5T MR-linac plan quality in patients with prostate cancer","volume":"24","author":"Tanaka","year":"2023","journal-title":"J Appl Clin Med Phys"},{"issue":"17","key":"10.1016\/j.canrad.2026.104810_bib1000","doi-asserted-by":"crossref","first-page":"175004","DOI":"10.1088\/1361-6560\/aceb2c","article-title":"Performance assessment of variant UNet-based deep-learning dose engines for MR-linac-based prostate IMRT plans","volume":"68","author":"Tseng","year":"2023","journal-title":"Phys Med Biol"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.canrad.2026.104810_bib1005","first-page":"65","article-title":"MRI-guided radiotherapy for prostate cancer: a new paradigm","volume":"61","author":"Murgi\u0107","year":"2022","journal-title":"Acta Clin Croat"},{"issue":"1","key":"10.1016\/j.canrad.2026.104810_bib1010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13014-021-01858-7","article-title":"Dosimetric comparison of MR-linac-based IMRT and conventional VMAT treatment plans for prostate cancer","volume":"16","author":"Da Silva Mendes","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104810_bib1015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2022.07.004","article-title":"First experimental demonstration of VMAT combined with MLC tracking for single and multifraction lung SBRT on an MR-linac","volume":"174","author":"Uijtewaal","year":"2022","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2026.104810_bib1020","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/abd66d","article-title":"Proof-of-concept delivery of intensity modulated arc therapy on the Elekta Unity 1.5T MR-linac","volume":"66","author":"Kontaxis","year":"2021","journal-title":"Phys Med Biol"},{"issue":"4","key":"10.1016\/j.canrad.2026.104810_bib1025","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2024.10.028","article-title":"Enhancing delivery efficiency on the magnetic resonance-linac: a comprehensive evaluation of prostate stereotactic body radiation therapy using volumetric modulated arc therapy","volume":"122","author":"Snyder","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.canrad.2026.104810_bib1030","doi-asserted-by":"crossref","first-page":"e1378","DOI":"10.1200\/JOP.19.00605","article-title":"Time-driven activity-based costing comparison of CT-guided versus MR-guided SBRT","volume":"16","author":"Parikh","year":"2020","journal-title":"JCO Oncol Pract"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321826000132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321826000132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:38:24Z","timestamp":1782905904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321826000132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1278321826000132"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2026.104810","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Magnetic resonance imaging-guided radiotherapy for prostate cancer: A systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2026.104810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104810"}}